Lai Wang is Global Head of R&D at BeiGene, Ltd. (BGNE). They have made 18 open-market trades across 2 companies since 2021, most recently 2026-06-23.
CIK 0001852291
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 18 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ONC | 1,710,085 | $631.5M |
| BGNE | 990,171 | $182.9M |
| Total | $814.4M |
Shares reported on the most recent Form 4, priced at the 2026-06-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ONC | SELL | 2026-06-23 | 2026-06-25 | $276.74 | $296K | +9.5% | +18.2% | +32.5% |
| ONC | SELL | 2026-06-16 | 2026-06-18 | $265.39 | $310K | +8.8% | +16.2% | +30.5% |
| ONC | SELL | 2026-06-11 | 2026-06-15 | $261.00 | $197K | +4.9% | +16.8% | +32.7% |
| ONC | SELL | 2026-06-08 | 2026-06-10 | $269.38 | $368K | +7.0% | +15.6% | +36.1% |
| ONC | SELL · 10b5-1 | 2025-09-09 | 2025-09-11 | $350.06 | $1.8M | -0.8% | -1.4% | -2.7% |
| ONC | SELL · 10b5-1 | 2025-07-29 | 2025-07-31 | $302.88 | $1.6M | -0.2% | +15.0% | +9.1% |
| ONC | SELL · 10b5-1 | 2025-07-18 | 2025-07-22 | $300.00 | $210K | +1.0% | +6.1% | +7.6% |
| ONC | SELL | 2025-06-23 | 2025-06-25 | $260.00 | $267K | -7.0% | +10.9% | +25.2% |
| ONC | SELL | 2025-06-16 | 2025-06-18 | $262.11 | $863K | +0.3% | +20.5% | +33.8% |
| ONC | SELL | 2025-06-06 | 2025-06-10 | $252.33 | $405K | -1.0% | -2.5% | +33.3% |
| BGNE | SELL · 10b5-1 | 2025-02-21 | 2025-02-25 | $257.11 | $2.5M | N/A | N/A | N/A |
| BGNE | SELL · 10b5-1 | 2024-09-27 | 2024-10-01 | $220.35 | $1.1M | -0.1% | -14.2% | -22.2% |
| BGNE | SELL | 2024-06-24 | 2024-06-26 | $159.80 | $340K | +1.6% | +14.2% | +47.1% |
| BGNE | SELL | 2024-06-17 | 2024-06-20 | $156.74 | $575K | -6.2% | +4.9% | +28.6% |
| BGNE | SELL | 2023-06-26 | 2023-06-27 | $181.91 | $402K | +8.4% | +17.9% | +7.2% |
| BGNE | SELL | 2023-06-20 | 2023-06-20 | $192.42 | $510K | -6.2% | +1.5% | +9.9% |
| BGNE | SELL | 2023-06-07 | 2023-06-09 | $224.74 | $104K | -14.7% | -11.7% | -10.9% |
| BGNE | SELL | 2022-06-27 | 2022-06-28 | $177.32 | $162K | +9.3% | +7.9% | -18.6% |
| BGNE | SELL | 2022-06-17 | 2022-06-22 | $146.75 | $278K | +24.9% | +16.0% | -1.2% |
| BGNE | SELL | 2022-06-06 | 2022-06-08 | $142.00 | $94K | -2.0% | +21.2% | +5.0% |
| BGNE | SELL | 2021-06-28 | 2021-06-30 | $362.48 | $330K | -3.7% | -7.8% | +6.0% |
| BGNE | SELL | 2021-06-18 | 2021-06-21 | $331.15 | $531K | +8.9% | -4.5% | +24.1% |
| BGNE | SELL | 2021-06-07 | 2021-06-09 | $354.26 | $465K | -6.2% | -5.1% | -0.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.